Gonadorelin

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH). It stimulates the release of LH and FSH from the anterior pituitary. FDA-approved for diagnostic evaluation of pituitary gonadotropin function. Clinically, GnRH analogs (agonists and antagonists) are more commonly used.

PubMed results: 291 · Human studies: 116 · Animal studies: 241

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

• Subcutaneous — standard range 100 mcg, Diagnostic test

10-40 minutes (high confidence)

• Pituitary gonadotropin release research (Strong clinical): As synthetic gonadotropin-releasing hormone (GnRH), gonadorelin has been extensively studied for stimulating LH and FSH release from the anterior pituitary and is used in diagnostic evaluation of pituitary gonadotropin function
• Reproductive axis assessment (Strong clinical): Clinical research has employed gonadorelin stimulation testing to characterize hypothalamic-pituitary-gonadal axis integrity in contexts including hypogonadism and delayed puberty evaluation
• Prostate carcinoma research contexts (Moderate clinical): GnRH pathway agents, including gonadorelin-related analogs, have been studied in prostate carcinoma research programs examining androgen-axis modulation across localized and biochemically recurrent disease stages

• Transient flushing or headache — Mild, Common. Clinical literature on GnRH administration commonly notes mild, transient vasomotor symptoms and headache related to acute pituitary gonadotropin release
• Injection site reactions — Mild, Uncommon. Parenteral research and diagnostic use has been associated with local injection-site discomfort in some study settings
• Nausea — Mild, Uncommon. Gastrointestinal discomfort has been reported in clinical GnRH testing literature, generally mild and self-limited

• Hormone-dependent malignancy research cautions (Clinical): Because gonadorelin stimulates LH/FSH and downstream sex-steroid pathways, research frameworks apply caution in settings where gonadotropin-driven hormonal stimulation is undesirable, including certain hormone-sensitive tumor contexts
• Pituitary or hypothalamic lesions altering gonadotropin response (Clinical): Diagnostic GnRH testing may yield uninterpretable or atypical responses when structural pituitary or hypothalamic disease is present, limiting research and clinical utility of stimulation assays

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT05320406 — RElugolix VErsus LeUprolide Cardiac Trial (PHASE2), status: ACTIVE_NOT_RECRUITING. Indications: Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
• NCT06291064 — Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2), status: RECRUITING. Indications: Triple Negative Breast Cancer
• NCT01294371 — Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin), status: COMPLETED. Indications: Genital Endometriosis
• NCT00004344 — Purification of Testis-Stimulating Factor in Precocious Puberty, status: COMPLETED. Indications: Precocious Puberty
• NCT00064987 — Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism (PHASE2), status: TERMINATED. Indications: Hypogonadism, Kallmann Syndrome
• NCT03209492 — Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer", status: COMPLETED. Indications: Prostate Cancer
• NCT06312670 — Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer (PHASE2), status: COMPLETED. Indications: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
• NCT02313051 — Everolimus trIal for Advanced prememopausaL Breast Cancer Patients (PHASE2), status: UNKNOWN. Indications: Metastatic Breast Cancer
• NCT00587431 — Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer (PHASE2), status: COMPLETED. Indications: Prostate Cancer
• NCT03009981 — A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (PHASE3), status: COMPLETED. Indications: Prostate Cancer
• NCT03680053 — Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (NA), status: TERMINATED. Indications: Infertility, ART
• NCT06970457 — The Interaction of Body Composition, Sex Hormones and Exercise in Men (NA), status: RECRUITING. Indications: Normal-weight Obesity
• NCT06913075 — FET in Adenomyosis (NA), status: NOT_YET_RECRUITING. Indications: Adenomyosis
• NCT02635607 — Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol (NA), status: UNKNOWN. Indications: Infertility
• NCT03236545 — Menopause Effects on Vascular Function (NA), status: COMPLETED. Indications: Cardiovascular Risk Factor
• NCT01467882 — Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty (PHASE3), status: COMPLETED. Indications: Central Precocious Puberty
• NCT07097259 — A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants (PHASE1), status: COMPLETED. Indications: Hypogonadism
• NCT06513962 — Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer (PHASE3), status: RECRUITING. Indications: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
• NCT02603679 — Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PHASE2), status: ACTIVE_NOT_RECRUITING. Indications: Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
• NCT05110170 — Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (PHASE3), status: COMPLETED. Indications: Breast Cancer